Global Infectious Disease Diagnostics Market - Analysis of Market Size, Share & Trends for 2019 – 2020 and Forecast to 2027
The global infectious disease diagnostics market is expected to grow at a CAGR of 7.9% from 2020 to reach 41.6 billion by 2027. The growth is primarily attributed to prevalence of infectious diseases, global outbreak of COVID-19, technological advancements, and increased demands for decentralized diagnostic POC kits. However, unfavourable and inadequate reimbursement scenarios can impact the growth of the market.
By Product: Reagents, kits and Consumables dominated the infectious disease diagnostics market in 2020
Reagents, kits and consumables segment accounted for the largest share of infectious disease diagnostics market. The largest share of this segment is mainly attributed to frequent purchase of these products due to their recurrent usage.
POC testing segment to account for fastest growth
By type of testing, infectious disease diagnostics market is segmented into laboratory testing and POC testing. During the forecast period, POC testing accounted for fastest growth. Highest CAGR can be attributed to faster diagnosis and need to closely monitor patients.
By Technology: Immunodiagnostics segment accounted for largest share
On the basis of technology, infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays and other technologies. Immunodiagnostics segment accounted for largest share in 2020. The growth of this segment was mainly attributed to increasing demand for immunoassays in COVID-19 testing, POC infectious disease testing, rising trend for automation and development of immunodiagnostic tests.
By Disease: Hepatitis to hold the largest share of Infectious disease diagnostics market
By disease type, hepatitis segment held the largest share of infectious disease diagnostics market in 2020. The growth is mainly driven by increasing blood transfusions and donations, prevalence of hepatitis B & C infections, rising geriatric population and benefits offered by POC instruments and kits.
Diagnostic laboratory: Accounted for largest share of Infectious disease diagnostics market
By end user, diagnostic laboratory segment accounted for highest CAGR. This can be attributed to strengthening of healthcare infrastructure and prevalence of infectious disease.
By Region: Asia Pacific fastest growing market
In 2020, North America accounted for the largest share of infectious disease diagnostics. The largest share is mainly attributed to highly developed healthcare system in US and Canada, availability of leading national clinical laboratories and technologically advanced instruments. However, Asia Pacific region is expected to grow at fastest CAGR during the forecast period. The growth is driven by rapid urbanization, government initiatives, increased investments on healthcare system and improved accessibility to diagnostic services.
Competitive Scenario
Abbott Laboratories (US)
F. Hoffmann-La Roche Ltd(Switzerland)
bioM?rieux SA (France)
Thermo Fisher Scientific Inc. (US)
Danaher Corporation (US)
Quidel Corporation (US)
Hologic, Inc. (US)
Siemens Healthineers AG (Germany)
Becton, Dickinson and Company (US)
PerkinElmer Inc. (US)
QIAGEN (Netherlands)
Grifols S.A. (Spain)
DiaSorin S.p.A (Italy)
Bio-Rad Laboratories Inc. (US)
Sysmex Corporation (Japan)
Ortho Clinical Diagnostics (US)
Luminex Corporation (US)
Meridian Bioscience (US)
Genetic Signatures (Australia)
OraSure Technologies (US)
Trinity Biotech Plc. (Ireland)
Chembio Diagnostic Systems
Inc. (US)
Seegene Inc. (South Korea)
Co-Diagnostics Inc. (US)
ELITechGroup (France)
Epitope Diagnostics, Inc. (US)
Trivitron Healthcare (India)
Meril Life Sciences Pvt. Ltd. (India)
InBios International Inc. (US)
and ABACUS Diagnostica Oy (Finland)
By Product: Reagents, kits and Consumables dominated the infectious disease diagnostics market in 2020
Reagents, kits and consumables segment accounted for the largest share of infectious disease diagnostics market. The largest share of this segment is mainly attributed to frequent purchase of these products due to their recurrent usage.
POC testing segment to account for fastest growth
By type of testing, infectious disease diagnostics market is segmented into laboratory testing and POC testing. During the forecast period, POC testing accounted for fastest growth. Highest CAGR can be attributed to faster diagnosis and need to closely monitor patients.
By Technology: Immunodiagnostics segment accounted for largest share
On the basis of technology, infectious disease diagnostics market is segmented into immunodiagnostics, clinical microbiology, PCR, INAAT, DNA sequencing & NGS, DNA microarrays and other technologies. Immunodiagnostics segment accounted for largest share in 2020. The growth of this segment was mainly attributed to increasing demand for immunoassays in COVID-19 testing, POC infectious disease testing, rising trend for automation and development of immunodiagnostic tests.
By Disease: Hepatitis to hold the largest share of Infectious disease diagnostics market
By disease type, hepatitis segment held the largest share of infectious disease diagnostics market in 2020. The growth is mainly driven by increasing blood transfusions and donations, prevalence of hepatitis B & C infections, rising geriatric population and benefits offered by POC instruments and kits.
Diagnostic laboratory: Accounted for largest share of Infectious disease diagnostics market
By end user, diagnostic laboratory segment accounted for highest CAGR. This can be attributed to strengthening of healthcare infrastructure and prevalence of infectious disease.
By Region: Asia Pacific fastest growing market
In 2020, North America accounted for the largest share of infectious disease diagnostics. The largest share is mainly attributed to highly developed healthcare system in US and Canada, availability of leading national clinical laboratories and technologically advanced instruments. However, Asia Pacific region is expected to grow at fastest CAGR during the forecast period. The growth is driven by rapid urbanization, government initiatives, increased investments on healthcare system and improved accessibility to diagnostic services.
Competitive Scenario
Abbott Laboratories (US)
F. Hoffmann-La Roche Ltd(Switzerland)
bioM?rieux SA (France)
Thermo Fisher Scientific Inc. (US)
Danaher Corporation (US)
Quidel Corporation (US)
Hologic, Inc. (US)
Siemens Healthineers AG (Germany)
Becton, Dickinson and Company (US)
PerkinElmer Inc. (US)
QIAGEN (Netherlands)
Grifols S.A. (Spain)
DiaSorin S.p.A (Italy)
Bio-Rad Laboratories Inc. (US)
Sysmex Corporation (Japan)
Ortho Clinical Diagnostics (US)
Luminex Corporation (US)
Meridian Bioscience (US)
Genetic Signatures (Australia)
OraSure Technologies (US)
Trinity Biotech Plc. (Ireland)
Chembio Diagnostic Systems
Inc. (US)
Seegene Inc. (South Korea)
Co-Diagnostics Inc. (US)
ELITechGroup (France)
Epitope Diagnostics, Inc. (US)
Trivitron Healthcare (India)
Meril Life Sciences Pvt. Ltd. (India)
InBios International Inc. (US)
and ABACUS Diagnostica Oy (Finland)
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
5. MARKET OVERVIEW
5.1. Introduction
5.2. Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
5.2.4. Challenges
5.3. COVID-19 Impact of the Infectious Disease Diagnostics Market
6. INDUSTRY INSIGHTS
6.1. Introduction
6.2. Industry Trends
7. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
7.1. Introduction
7.2. Reagents, kits & consumables
7.3. Instruments
7.4. Software & services
8. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2019-2027 (USD MILLION)
8.1. Laboratory Testing
8.2. POC Testing
9. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2027 (USD MILLION)
9.1. Immunodiagnostics
9.2. Clinical Microbiology
9.3. PCR
9.4. INAAT
9.5. DNA Sequencing & NGS
9.6. DNA Microarrays
9.7. Other Technologies
10. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2027 (USD MILLION)
10.1. COVID-19
10.2. HIV
10.3. HAIs
10.4. Hepatitis
10.5. CT/NG
10.6. HPV
10.7. TB
10.8. Influenza
10.9. Other Infectious Diseases
11. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2027 (USD MILLION)
11.1. Diagnostics Laboratories
11.2. Hospitals & Clinics
11.3. Academic Research Institutes
11.4. Other End Users
12. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY GEOGRAPHY, 2019-2027 (USD MILLION)
12.1. North America
12.1.1. US
12.1.2. Canada
12.2. Europe
12.2.1. Germany
12.2.2. UK
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Rest of Europe
12.3. Asia-Pacific
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Rest of Asia-Pacific
12.4. Rest of the World
12.4.1. Latin America
12.4.2. Middle East & Africa
13. COMPETITIVE LANDSCAPE
13.1. Introduction
13.2. Market Share Analysis
13.3. Competitive Situation and Trends
13.3.1. Product Launches
13.3.2. Partnerships, Collaborations and Agreements
13.3.3. Acquisitions
13.3.4. Expansions
13.3.5. Other Developments
14. COMPANY PROFILES
14.1. Abbott Laboratories (US)
14.2. F. Hoffmann-La Roche Ltd (Switzerland)
14.3. bioM?rieux SA (France)
14.4. Thermo Fisher Scientific Inc. (US)
14.5. Danaher Corporation (US)
14.6. Quidel Corporation (US)
14.7. Hologic, Inc. (US)
14.8. Siemens Healthineers AG (Germany)
14.9. Becton, Dickinson and Company (US)
14.10. PerkinElmer Inc. (US)
14.11. QIAGEN (Netherlands)
14.12. Grifols S.A. (Spain)
14.13. DiaSorin S.p.A (Italy)
14.14. Bio-Rad Laboratories, Inc. (US)
14.15. Sysmex Corporation (Japan)
14.16. Ortho Clinical Diagnostics (US)
14.17. Luminex Corporation (US)
14.18. Meridian Bioscience (US)
14.19. Genetic Signatures (Australia)
14.20. OraSure Technologies (US)
14.21. Trinity Biotech Plc. (Ireland)
14.22. Chembio Diagnostic Systems, Inc. (US)
14.23. Seegene Inc. (South Korea)
14.24. Co-Diagnostics, Inc. (US)
14.25. ELITechGroup (France)
14.26. Epitope Diagnostics, Inc. (US)
14.27. Trivitron Healthcare (India)
14.28. Meril Life Sciences Pvt. Ltd. (India)
14.29. InBios International, Inc. (US)
14.30. ABACUS Diagnostica Oy (Finland).
15. APPENDIX
15.1. Discussion Guide
15.2. Available Customizations
15.3. Related Reports
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
5. MARKET OVERVIEW
5.1. Introduction
5.2. Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
5.2.4. Challenges
5.3. COVID-19 Impact of the Infectious Disease Diagnostics Market
6. INDUSTRY INSIGHTS
6.1. Introduction
6.2. Industry Trends
7. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
7.1. Introduction
7.2. Reagents, kits & consumables
7.3. Instruments
7.4. Software & services
8. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2019-2027 (USD MILLION)
8.1. Laboratory Testing
8.2. POC Testing
9. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2027 (USD MILLION)
9.1. Immunodiagnostics
9.2. Clinical Microbiology
9.3. PCR
9.4. INAAT
9.5. DNA Sequencing & NGS
9.6. DNA Microarrays
9.7. Other Technologies
10. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2019-2027 (USD MILLION)
10.1. COVID-19
10.2. HIV
10.3. HAIs
10.4. Hepatitis
10.5. CT/NG
10.6. HPV
10.7. TB
10.8. Influenza
10.9. Other Infectious Diseases
11. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2019-2027 (USD MILLION)
11.1. Diagnostics Laboratories
11.2. Hospitals & Clinics
11.3. Academic Research Institutes
11.4. Other End Users
12. GLOBAL INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY GEOGRAPHY, 2019-2027 (USD MILLION)
12.1. North America
12.1.1. US
12.1.2. Canada
12.2. Europe
12.2.1. Germany
12.2.2. UK
12.2.3. France
12.2.4. Italy
12.2.5. Spain
12.2.6. Rest of Europe
12.3. Asia-Pacific
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Rest of Asia-Pacific
12.4. Rest of the World
12.4.1. Latin America
12.4.2. Middle East & Africa
13. COMPETITIVE LANDSCAPE
13.1. Introduction
13.2. Market Share Analysis
13.3. Competitive Situation and Trends
13.3.1. Product Launches
13.3.2. Partnerships, Collaborations and Agreements
13.3.3. Acquisitions
13.3.4. Expansions
13.3.5. Other Developments
14. COMPANY PROFILES
14.1. Abbott Laboratories (US)
14.2. F. Hoffmann-La Roche Ltd (Switzerland)
14.3. bioM?rieux SA (France)
14.4. Thermo Fisher Scientific Inc. (US)
14.5. Danaher Corporation (US)
14.6. Quidel Corporation (US)
14.7. Hologic, Inc. (US)
14.8. Siemens Healthineers AG (Germany)
14.9. Becton, Dickinson and Company (US)
14.10. PerkinElmer Inc. (US)
14.11. QIAGEN (Netherlands)
14.12. Grifols S.A. (Spain)
14.13. DiaSorin S.p.A (Italy)
14.14. Bio-Rad Laboratories, Inc. (US)
14.15. Sysmex Corporation (Japan)
14.16. Ortho Clinical Diagnostics (US)
14.17. Luminex Corporation (US)
14.18. Meridian Bioscience (US)
14.19. Genetic Signatures (Australia)
14.20. OraSure Technologies (US)
14.21. Trinity Biotech Plc. (Ireland)
14.22. Chembio Diagnostic Systems, Inc. (US)
14.23. Seegene Inc. (South Korea)
14.24. Co-Diagnostics, Inc. (US)
14.25. ELITechGroup (France)
14.26. Epitope Diagnostics, Inc. (US)
14.27. Trivitron Healthcare (India)
14.28. Meril Life Sciences Pvt. Ltd. (India)
14.29. InBios International, Inc. (US)
14.30. ABACUS Diagnostica Oy (Finland).
15. APPENDIX
15.1. Discussion Guide
15.2. Available Customizations
15.3. Related Reports
